Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
HOME > Special Interview on Long-Listed Products and Generic Drugs
Special Interview on Long-Listed Products and Generic Drugs
-
Astem Pres. Yoshimura Says Wholesalers Should Break Away from Dependence on Long-Listed Drugs
April 4, 2013
-
MOF Budget Examiner Hirotsugu Shinkawa Hopes to See New Generic Target Set at Highest Share Achievable at Fastest Pace
March 29, 2013
-
CSIMC Expert Member Yoshiaki Kamoya (Executive Officer, Shionogi) Says Price Cuts for Long-Listed Drugs and Perpetuation of Premium for New Drug Development Should Be Discussed Together
March 22, 2013
-
Japan Pharmaceutical Association Vice President Hirotsugu Miura Says that 70% Rule for New Generics Will Be Debatable in Future
March 15, 2013
-
Japan Health Insurance Association President Tsuyoshi Kobayashi Points Out that Price Competition Will Not Work If Prices Are Set Equally
March 12, 2013
-
Kyoto Medical Association Vice President Hideki Adachi Says Drug Makers Should Closely Verify NHI Prices and Development Costs of Each Drug
March 8, 2013
-
Shuji Shirakawa of Kenporen Says Long-Listed Product Price Cuts Irrelevant to New Drug Development Premium
February 28, 2013
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The advance of cell therapy is one of the most exciting innovations in medical treatment in recent years. These drugs offer potential curative treatments for severe or previously fatal diseases. In this article, I will explain features and challenges in…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…